Cartesian Therapeutics appoints Chief Scientific Officer
Cartesian Therapeutics, a biopharma company pioneering RNA cell therapy for autoimmune diseases and cancer, has appointed Christopher M. Jewell, PhD/MS as Chief Scientific Officer.
Dr. Jewell’s predecessor, Michael Singer, MD, PhD, has been named Chairman of the Board and Chief Strategy Officer.
Dr. Jewell is a leader in the immune engineering and nanotechnology fields. Over the past decade at the University of Maryland as the MPower Professor and Minta Martin Professor, he secured over $25m in funding and published 125 manuscripts and patents, including papers in Nature, Nature Biotechnology, Nature Materials, and others.
Dr. Jewell has received over 50 awards, including the Presidential Early Career Award for Scientists and Engineers (PECASE). He is also an elected fellow of numerous professional societies. Dr. Jewell’s translational medicine skills benefit from his experience at Boston Consulting Group and as an advisor to dozens of drugmakers over the past 15 years.
Cartesian’s lead asset, Descartes-08, is a RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase 2b clinical development for patients with generalized myasthenia gravis. Cartesian operates a wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD.
